Table 1

Patient characteristics of 1987 undifferentiated arthritis patients and 2010 undifferentiated arthritis patients, at first presentation

Characteristic1987 Undifferentiated arthritis (n=1166)2010 Undifferentiated arthritis (n=776)p Value
Age, mean±SD, years51.6±17.150.3±17.20.12
Female sex699 (59.9)443 (57.1)0.21
BMI, mean±SD, kg/m225.9±4.325.6±4.40.26
Current or past smoker286 (28.0)197 (29.1)0.97
Onset of symptoms
 (Sub)acute657 (58.8)465 (62.4)0.12
 Gradual460 (41.2)280 (37.6)
Morning stiffness, median (IQR), min30 (0–60)30 (0–60)0.06
 0–29457 (41.0)337 (45.6)0.14
 30–59190 (17.0)117 (15.8)
 ≥60468 (42.0)285 (38.6)
Symptom duration, median (IQR), weeks15.7 (6.9–31.9)13.4 (5.3–29.2)0.01
Localisation of affected joints
Small joints hands/feet908 (81.1)631 (84.8)0.04
Localisation of affected joints
 Symmetrical563 (54.0)328 (47.7)0.01
Localisation of affected joints
 Upper extremities722 (72.1)507 (75.7)0.10
Swollen joint count, median (IQR)3 (1–7)2 (1–5)<0.001
 0–3 joints607 (53.1)494 (65.3)<0.001
 4–10 joints364 (31.8)218 (28.8)
 >10 joints172 (15.0) 44 (5.8)
Tender joint count, median (IQR)5 (2–12)2 (1–6)<0.001
 0–3 joints301 (40.2)266 (59.2)<0.001
 4–10 joints223 (29.8)158 (35.2)
 >10 joints225 (30.0)25 (5.6)
ESR, median (IQR), mm/h19 (8–39)16 (8–36)0.02
CRP, median (IQR), mg/l9 (3–24.5)8 (3–23)0.29
RF positive294 (25.5)76 (9.9)<0.001
 Low positive118 (10.2)32 (4.2)0.83
 High positive176 (15.3)44 (5.7)
Anti-CCP-2 positive234 (24.1)61 (9.6)<0.001
 Low positive44 (4.5)44 (6.9)<0.001
 High positive190 (19.6)17 (2.7)
HAQ, mean±SD0.8±0.70.7±0.60.01
2010 Criteria score, mean±SD4.9 (2.4)3.2 (1.4)<0.001
  • Except where indicated otherwise, values are the number (%) of patients.

  • interquartile range (IQR) Localisation of affected joint: ‘upper joints’ stands for upper joints with or without involvement of the lower joints, whereas ‘small joints’ stands for smaller joints with or without involvement of the large joints.

  • In the group of all patients with undifferentiated arthritis, some data were missing, as follows: for body mass index, n=351; for smoking, n=146; for onset of symptoms, n=48; for morning stiffness, n=51; for symptom duration, n=95; for small joints involved, n=46, for symmetrical joint involvement, n=123; for upper extremity joints involved, n=164; n=25; for erythrocyte sedimentation rate (ESR), n=8; for C-reactive protein (CRP), n=81; for rheumatoid factor (RF), n=11; for citrullinated protein antibodies (CCP), n=197; for health assessment questionnaire (HAQ) score, n=245.

  • A χ2 square test was used for nominal variables and the Student's t test or Mann–Whitney U-test for continuous variables. Student's t test was performed when variables are presented as mean and a Mann–Whitney U-test was performed when variables are presented as median.

  • RF, rheumatoid factor.